Related Experiment Video
Updated: Mar 7, 2026
Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion
Published on: February 24, 2021
Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series
Manish Suthar1, Saniya Gupta1, Suhail Bukhari2
1TotipotentRX Center for Cellular Medicine (Cesca Therapeutics Inc., USA), Fortis Memorial Research Institute, Gurgaon-122002, Delhi, (NCR), India.
Insights
Autologous Platelet Rich Plasma (PRP) effectively treats chronic non-healing lower extremity ulcers. This safe and cost-effective method significantly accelerates wound healing, reducing amputation risk.
Area of Science:
- Regenerative Medicine
- Wound Healing Research
- Biologics in Dermatology
Background:
- Non-healing ulcers pose a significant global health burden, often leading to lower limb amputations.
- Autologous Platelet Rich Plasma (PRP) offers a promising, cost-effective treatment modality for chronic wounds.
- PRP contains growth factors that stimulate natural tissue repair processes.
Observation:
- A case series evaluated autologous PRP for chronic non-healing lower extremity ulcers in 24 patients.
- PRP was prepared using a rapid, point-of-care density gradient centrifugation system.
- Patients received a single dose of PRP injections and topical PRP gel.
Findings:
- All patients demonstrated wound healing, with a mean healing time of 8.2 weeks.
- A five-fold increase in platelet concentration was achieved with the point-of-care device.
- The average platelet dose administered was 70.10 × 10^8.
Implications:
- Autologous PRP shows potential as a safe and effective treatment for chronic non-healing ulcers.
- This approach may reduce the need for lower limb amputations.
- Further research can explore PRP's role in managing complex wounds.
Background:
Non-healing ulcers are a major health problem worldwide and have great impact at personal, professional and social levels, with high cost in terms of human and material resources. Recalcitrant non-healing ulcers are inevitable and detrimental to the lower limb and are a major cause of non-traumatic lower limb amputations. Application of autologous Platelet Rich Plasma (PRP) has been a major breakthrough for the treatment of non-healing and diabetic foot ulcers, as it is an easy and cost-effective method, and provides the necessary growth factors that enhance tissue healing. PRP is a conglomeration of thrombocytes, cytokines and various growth factors which are secreted by α-granules of platelets that augment the rate of natural healing process with decrease in time. The purpose of this case series was to evaluate the safety and efficacy of autologous platelet rich plasma for the treatment of chronic non-healing ulcers on the lower extremity.
Methods:
Autologous PRP was prepared from whole blood utilizing a rapid, intraoperative point-of-care system that works on the principle of density gradient centrifugation. Twenty Four (24) patients with non-healing ulcers of different etiologies, who met the inclusion criteria, were treated with single dose of subcutaneous PRP injections along with topical application of PRP gel under compassionate use.
Results:
The mean age of the treated patients was 62.5 ± 13.53 years and they were followed-up for a period of 24 weeks. All the patients showed signs of wound healing with reduction in wound size, and the mean time duration to ulcer healing was 8.2 weeks. Also, an average five fold increase in the platelet concentrate was observed in the final PRP product obtained using the rapid point-of-care device, and the average platelet dose administered to the patients was 70.10 × 108.
Conclusion:
This case series has demonstrated the potential safety and efficacy of autologous platelet rich plasma for the treatment of chronic non-healing ulcers.
Trial Registration:
NCT03026855 , Registered 4 January 2017 'Retrospectively'.
Related Concept Videos
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:27Peripheral Artery Disease III: Interprofessional Care